Marcus Anderson

Marc has a degree in economics and a MSc. in Finance. Marc worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Allied Healthcare Services (Nasdaq: AIQ) Receives Buyout Offer

Alliance Healthcare Services receives buyout offer – Nasdaq ticker: AKAO

Shares of AIQ are up over 13% on large volumes. Allied Healthcare operates outsourced healthcare services to hospitals and providers and trades under the Nasdaq ticker AIQ. Located in Newport Beach, CA, Allied Healthcare Services operates as partner to over 1,000 hospitals in 45 states. On Friday it closed at $7.95 but Monday’s close saw AIQ reaching $9.00 on news that Tahoe Investment Group has offered to acquire all the outstanding shares for $9.60 per share.

From Allied Healthcare’s press release:

“The Board of Directors of the Company has authorized a Special Committee, comprised solely of directors not affiliated with Tahoe, to evaluate the Expression of Interest. The Special Committee has engaged independent legal counsel and intends to engage an independent financial advisor to assist in its evaluation of the Expression of Interest. In connection with the Expression of Interest, the Special Committee has agreed to waive the provision of the Governance Agreement prohibiting THAIHOT and its affiliates, including Tahoe, from proposing to acquire additional shares of the Company’s common stock. The waiver is for the limited purpose of submitting the Expression of Interest to the Special Committee.”

Allied Healthcare Services sales have dropped from $493.70 million in 2011 to $473.10 million in 2015. Three firms cover AIQ and the most recent analyst activity shows a rating downgrade to “Market Perform” or “Neutral”.

Always perform your own due diligence before making any decisions regarding the buy or sale of any stock. The below data is provided without any guarantee of its accuracy.

Ticker Symbol AIQ
Last Price a/o 4:00 EST  $                  9.00
Average Volume 20,600
Market Cap $85.94 million
Sales $500.5 million
Shares Outstanding 10.8 million
Share Float 4.9 million
Shortable Yes
Optionable No
Inside Ownership 62.50%
Short Float 0.91%
Short Interest Ratio 2.15
Quarterly Return 21.20%
YTD Return -13.40%
Year Return -8.80%

Opthotech Corp (Nasdaq: OPHT) Shares Plunge

Market Mover Alert! Opthotech Corporation – Nasdaq ticker: OPHT

Shares of OPHT are down over 80% on large volumes. Opthotech Corporation announced that it did not meet its primary endpoints in a pivotal Phase 3 clinical trial. The trial was to measure the effectiveness of their drug candidate Fostiva in combination with Lucentis for the treatment of wet aged-related macular degeneration. Opthotech is a biopharmaceutical company specializing in the development of treatments to address diseases of the back of the eye.

On Friday OPHT closed at $38.77 but Monday’s close saw OPHT lows reaching $5.21. Such news underscores the risk inherent with biotechnology shares to the investment community.

From Opthotech’s press release:

“We are very disappointed in the results from these trials, particularly for patients afflicted with wet AMD,” commented David R. Guyer, M.D., Chief Executive Officer of Ophthotech. “We are thankful to the patients and clinical investigators and their staff for participating in the trials. We will continue to analyze the data from these two studies to better understand the trial results.”

Opthotech Corporation’s sales has grown from $0.00 in 2013 to $51.5 million in 2015. Several bulge-bracket investment banks cover OPHT and three this morning have downgraded the stock to “Neutral”.

Always perform your own due diligence before making any decisions regarding the buy or sale of any stock. The below data is provided without any guarantee of its accuracy.

Ticker Symbol OPHT
Last Price a/o 3:52 EST  $               5.27
Average Volume 1 million
Market Cap $1.38 Billion
Sales $50.4 million
Shares Outstanding 35.6 million
Share Float 35.5 million
Shortable Yes
Optionable Yes
Inside Ownership 5.48%
Short Float 11.41%
Short Interest Ratio 3.97
Quarterly Return -28.70%
YTD Return -50.60%
Year Return -41.20%

 

Achaogen Inc. (Nasdaq: AKAO) Spikes on Favorable Phase 3 News

Market Mover Alert! Acaogen Inc. – Nasdaq ticker: AKAO

Shares of AKAO are up over 70% on large volumes. Achaogen Inc. is a clinical stage biotech firm that develops anti-bacterials to treat drug-resistant infections. Achaogen Inc. trades under the Nasdaq ticker AKAO and is located in San Francisco, CA. On Friday it closed at $5.25 but Monday’s open saw AKAO reaching $8.70 on news that Achaogen’s lead drug, Plazomicin, met its Phase 3 objectives.

Plzomicin showed a lower rate of mortality or infection-related complications, when compared to colistin therapy. Those results moved Achaogen Inc. to announce that it will be submitting a New Drug Application to the FDA in 2017 and a marketing authorization application in 2018.

From Achaogen’s press release:

Achaogen Inc, sales have grown from $22.5 million in 2011 to $26.1 million in 2015. Three firms cover shares oa AKAO with either a “Buy” or “Neutral” rating assigned. The three analysts have assigned a target price of either $7, $10, or $15.

Always perform your own due diligence before making any decisions regarding the buy or sale of any stock. The below data is provided without any guarantee of its accuracy.

Ticker Symbol AKAO
Last Price a/o 9:00 EST  $               9.00
Average Volume 315,430
Market Cap $138 million
Sales $35.7 million
Shares Outstanding 26.3 million
Share Float 26.3 million
Shortable Yes
Optionable Yes
Inside Ownership 0.40%
Short Float 3.28%
Short Interest Ratio 2.73
Quarterly Return 16.93%
YTD Return -8.54%
Year Return -11.17%

 

 

General Finance Corp (Nasdaq: GFN) CEO Buys Shares

Market Mover Alert! General Finance Corp. – Nasdaq ticker: GFN

Shares of GFN are higher on large volumes. General Finance Corporation, located in Pasadena, CA, is a leading specialty rental services company that offers portable storage solutions globally. On December 7, 2016, they released Q1 results which included $62.8 million in revenues, a drop of $1 million from previous year’s Q1 figures. However General Finance Corp. CEO Ronald Valenta has recently acquired over 30,000 shares of GFN which seem to have motivated investors.

On December 2, shares ended the day at $4.05. Today GFN hit an intraday high of $4.95 on larger than normal volume.

From General Finance Corporation’s press release dated December 7, 2016:

First Quarter 2017 Highlights :

  • Total revenues were $62.8 million, compared to $63.8 million for the first quarter of fiscal year 2016.
  • Leasing revenues comprised 67% of total non-manufacturing revenues in both the first quarters of fiscal years 2017 and 2016.
  • Leasing revenues increased by 12%, excluding the oil and gas sector and the favorable foreign exchange impact.
  • Adjusted EBITDA was $13.0 million, compared to $13.9 million in the first quarter of fiscal year 2016.
  • Adjusted EBITDA margin was 21%, compared to 22% in the first quarter of fiscal year 2016.
  • Net loss attributable to common shareholders was $2.1 million, or $0.08 per diluted share, comparable to net loss attributable to common shareholders of $2.0 million, or $0.08 per diluted share, for the first quarter of fiscal year 2016.
  • Average fleet unit utilization was 73%, compared to 75% in the first quarter of fiscal year 2016.
  • Two acquisitions completed in North America during the quarter.

“Our North American leasing operations continued to benefit from geographic expansion and diversification,” said Ronald Valenta, President and Chief Executive Officer. “We delivered increased leasing revenues during the first quarter of fiscal year 2017 outside of the oil and gas sector. In September, we began to see positive signs in the energy sector, including increased drilling activity and improved fleet utilization. In the Asia-Pacific region, our non-oil and gas leasing revenues also increased, primarily driven by continued strength from the construction sector and a moderately higher Australian dollar relative to the U.S. dollar.”

Always perform your own due diligence before making any decisions regarding the buy or sale of any stock. The below data is provided without any guarantee of its accuracy.

Ticker Symbol GFN
Last Price 12/9/2016 11:30 EST  $               4.80
Average Volume 18,000
Market Cap $118 million
Sales $285 million
Shares Outstanding 26.3 million
Share Float 13.1 million
Shortable Yes
Optionable Yes
Inside Ownership 5.60%
Short Float 1.00%
Short Interest Ratio 7.15
Quarterly Return 3.69%
YTD Return 12.80%
Year Return 12.80%

Synergy Pharmaceuticals (Nasdaq: SGYP) Gets Good News

Big Volume on Synergy Pharmaceuticals Inc. – Nasdaq ticker: SGYP

Synergy Pharmaceuticals Inc said, according to preliminary data analysis, its experimental once-daily pill, Plecanatide, showed positive results in a late-stage study on irritable bowel syndrome patients. The company plans to apply to market the drug in 2017. Pre-market trading in SGYP saw the shares reach over $6.50 and have now settled back to yesterday’s trading levels.

Based in New York City, Synergy Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies.

Gary S. Jacob, Ph.D., Chairman and CEO of Synergy Pharmaceuticals Inc. said “We are very pleased with these results. These data reinforce our strong belief that Plecanatide may represent an important new treatment option for the millions of patients currently suffering from IBS-C. We look forward to the results of our second phase 3 IBS-C trial with Plecanatide later this month.”

Volumes on SGYP surged on the news – doubling the average daily volume less than an hour after the Nasdaq opened for trading. In November Synergy Pharmaceuticals presented a corporate update at the Jeffries London Healthcare conference. Shares moved significantly higher after that presentation on good volumes. Three analysts cover SGYP and all give the stock a “Buy” rating with price targets ranging from $7 to $15.

Always perform your own due diligence before making any decisions regarding the buy or sale of any stock. The below data is provided without any guarantee of its accuracy.

Ticker Symbol SGYP
Last Price 12/9/2016 10:00 EST  $               5.71
Average Volume 2.9 million
Market Cap $961 million
Sales
Shares Outstanding 173.5 million
Share Float 172 million
Shortable Yes
Optionable Yes
Inside Ownership 7.00%
Short Float 16.20%
Short Interest Ratio 9.72
Quarterly Return 13.52%
YTD Return -2.30%
Year Return -9.00%

Pure Storage (NYSE: PSTG) – Ready to Burn the Shorts?

Time to Buy Pure Storage Inc.? – Nasdaq ticker: PSTG

Pure Storage, Inc., headquartered in Mountain View, California invented all-flash enterprise storage. It operates primarily in the United States, Europe, and Asia. The company serves cloud-based software and service providers, e-commerce, education, energy, financial services, governments, healthcare, manufacturing, media, retail, and telecommunications sectors.

Recently the website InsiderMonkey.com claimed that PSTG is the #1 stock pick of the hedge fund community. They write “At the end of the third quarter, a total of 17 of the hedge funds tracked by Insider Monkey were bullish on this stock, a change of 21% from the second quarter of 2016. On the other hand, there were a total of 14 hedge funds with a bullish position in PSTG at the beginning of this year.” Investors should take note, however, that there appears to be large short positions on PSTG.

Over ten Wall St. investment banks provide coverage on Pure Storage Inc. including JP Morgan, Susquehanna, UBS, and Barclay’s. Their current reported ratings range from “Hold” to “Buy” with price targets ranging from $11 to $27. Yesterday, Thursday December 8, 2016, PSTG closed at $12.33.

While PSTG’s historical EPS was negative and falling, their most recently disclosed numbers saw a narrowing of EPS loss – beating street estimates. Pure Storage reported its Q3 earnings results on Wednesday, November 30th. The company reported a loss of $0.10 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of -$0.15 by $0.05. The company earned $197 million during the quarter, compared to analyst estimates of $192.36 million. Sales have not been a concern for holders of PSTG. In 2014 sales were a reported $$42.7 million growing to over $440 million in 2016.

Always perform your own due diligence before making any decisions regarding the buy or sale of any stock. The below data is provided without any guarantee of its accuracy.

Ticker Symbol PSTG
Last Price 12/8/2016 2:25 EST  $             12.33
Average Volume 1.1 million
Market Cap 2.4 Billion
Sales $650 million
Shares Outstanding 192.8 million
Share Float 71.3 million
Shortable Yes
Optionable Yes
Inside Ownership
Short Float 23.55%
Short Interest Ratio 14.54
Quarterly Return 1.23%
YTD Return 20.80%
Year Return -29.78%

 

Majesco Entertainment (Nasdaq: COOL) Announces Merger

Market Mover Alert on Majesco Entertainment – Nasdaq ticker: COOL

Majesco Entertainment is up over 60% today on large volumes. Majesco Entertainment trades on the Nasdaq under the ticker COOL.

The company is based in Edison, NJ. Majesco develops video games for the mass market featuring casual and family oriented titles for console and mobile platforms. Majesco Entertainment is over 25 years old and has distribution through retailers such as WalMart, GameStop, Best Buy, Toys ‘R Us, and Target.

The shares of COOL seem to be responding to a merger agreement between Majesco and PalarityTE Inc. – a innovative regenerative medicine company that develops products for plastic and reconstructive surgeries. The merger has been approved by the board of directors of both companies.

Dr. Edward Swanson, COO, stated, “PolarityTE will change the landscape of regenerative medicine, beginning with our first target tissue: skin. Prior to the groundbreaking discovery by Dr. Lough, the world had never seen true regeneration of functional skin, including all layers and hair. Skin regeneration of this magnitude is thought of as the holy grail by burn surgeons.” 

COOL shares once traded above $120. At the time of this writing they are trading around $5.28. The merger may be an attempt to grow revenues as sales have slid from over $130 million in 2012 to a mere $6.7 million in 2015.

Always perform your own due diligence before making any decisions regarding the buy or sale of any stock. The below data is provided without any guarantee of its accuracy.

Ticker Symbol COOL
Last Price a/o 2:25 EST  $               5.16
Average Volume 24,700
Market Cap $8.7 million
Sales $1.7 million
Shares Outstanding 2.77 million
Share Float 1.9 million
Shortable Yes
Optionable No
Inside Ownership
Short Float 3.03%
Short Interest Ratio 2.33
Quarterly Return -14.60%
YTD Return -28.20%
Year Return -35.07%

 

 

Voyager Therapeutics (Nasdaq: VYGR) Receives Positive News

Market Mover Alert on Voyager Therapeutics – Nasdaq ticker: VYGR

Voyager Therapeutics is up over 15% in early trading on heavy volume. Yesterday VYGR closed under $14.00 but today has seen it rise above $18.00 before settling back to the $16 handle.

Voyager Therapeutics is a gene therapy company that develops treatments for life threatening diseases of the central nervous system. Based in Cambridge, MA, Voyager Therapeutics has products in its pipeline that address treatments for Parkinson’s disease, amyotrophic lateral sclerosis, Friedrich’s ataxia, Huntington’s disease, and Alzheimer’s. Voyager Therapeutics has a partnership with the University of Massachusetts’s Medical School.

The company has just announced that its Parkinson’s treatment showed efficacy in a small, early-stage study. CEO Steven Paul said that his goal is to begin a blind placebo-controlled trial by the end of next year. Shares of VYGR jumped 30% after this announcement.

Five firms have initiated coverage of the stock with target prices ranging between $15 and $47. Of the firms covering VYGR, one has a “Buy” rating on the stock while three others have an “Outperform” or equivalent rating, and one rates it “Neutral”.

Always perform your own due diligence before making any decisions regarding the buy or sale of any stock. The below data is provided without any guarantee of its accuracy.

Ticker Symbol VYGR
Last Price a/o 10:45 EST  $             15.98
Average Volume 58,000
Market Cap $353.3 million
Sales $16.8 million
Shares Outstanding 25.7 million
Share Float 22.5 million
Shortable Yes
Optionable No
Inside Ownership
Short Float 3.43%
Short Interest Ratio 13.3
Quarterly Return 6.77%
YTD Return -37.30%
Year Return -58.40%

SunPower Corp (Nasdaq: SPWR) Announces Restructuring

Market Mover Alert on SunPower Corporation – Nasdaq ticker: SPWR

SunPower Corporation, majority owned by French energy giant Total SA, is up over 15% in heavy trading today. Investors seem to be positively responding to today’s news that Sunpower Corporation will be laying off 2,500 workers and closing a plant located in the Philippines as part of a company-wide restructuring effort. The company expects the move to move it into positive cashflow for 2017.

SunPower considers itself at the forefront of solar power innovation. The company operates in the residential, governmental, and utility sectors. Its headquarters are in San Jose, California and has offices in North America, Europe, Asia, and Africa.

The industry has been experiencing pricing pressures but the company expects some relief in the latter half of 2017. SunPower Corporation said that the average price for its products had decreased 25%. This is what most analysts believe will contribute to the company’s losses this quarter – its sixth quarterly loss in a row. SunPower said it expects to incur restructuring and other charges totaling about $200 million in the current quarter and restructuring charges of $225-$275 million through the end of 2017.

Shares of SPWR reacted positively to the news and had the effect of raising the share prices of other firms in the solar energy sector. SPWR has been a component stock of the Photovoltaik Global 30 Index since 2009

Always perform your own due diligence before making any decisions regarding the buy or sale of any stock. The below data is provided without any guarantee of its accuracy.

 

Ticker Symbol SPWR
Last Price a/o 2:45 EST  $           8.06
Average Volume 3 million
Market Cap $950 million
Sales $1.9 Billion
Shares Outstanding 135.9 million
Share Float 58.6 million
Shortable Yes
Optionable Yes
Inside Ownership 0.60%
Short Float 34.70%
Short Interest Ratio 6.7
Quarterly Return -31.80%
YTD Return -76.80%
Year Return -73.60%

 

Anthera Pharmaceuticals Inc (Nasdaq: ANTH) on the Move!

ANTH – Market Mover Alert!

Anthera Pharmaceuticals Inc., trading on the Nasdaq under ticker symbol ANTH, has seen a price a volume spike this morning. Anthera Pharmaceuticals recently elevated it President, Craig Thompson, to the Board level and to the position of CEO. Investors have responded to the news with volumes over ten time the normal trading volume in the first half-hour of trading; sending ANTH to an early morning gain of over 50%.

Anthera Pharmaceuticals Inc. is a California-based biotechnology company that focuses on innovative medicines. The company trades on the Nasdaq under the ticker symbol ANTH. They rely on two product candidates in development: Sollpura and Blisibimod. Sollpura is a biotechnology driven pancreatic replacement therapy for the potential treatment of exocrine pancreatic insufficiency in people suffering from cystic fibrosis. Blisibimod is a BAFF inhibitor for the potential treatment of systemic lupus erythematosus and IgA nephropathy. Company reports suggest that both drugs have made it through their respective Phase I and II clinical studies.

From Anthera Pharmaceuticals filing:

On December 2, 2016, upon recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”), Anthera Pharmaceuticals, Inc. (the “Company”) appointed Craig Thompson to serve on the Board as a Class I director and to serve as the Company’s Chief Executive Officer, effective December 6, 2016. Mr. Thompson will also continue to serve as the Company’s President.

Mr. Thompson was appointed to serve as the Company’s President and Chief Operating Officer effective January 7, 2016. Mr. Thompson, 50, has over 20 years of experience in pharmaceutical development and commercialization. Most recently he served as the Chief Operating Officer for Tetraphase Pharmaceuticals from February 2014 to December 2015, where he oversaw the development and implementation of the commercial strategy as well as the business development and commercial manufacturing. Prior to Tetraphase Pharmaceuticals, from January 2011 to December 2014, Mr. Thompson served as the Chief Commercial Officer for Trius Therapeutics resulting in the acquisition of Trius by Cubist Pharmaceuticals for over $700 million. Prior to Trius Therapeutics, Mr. Thompson held various positions of increasing responsibility with Pfizer from November 2003 to December 2010, with his last position as Vice President of Marketing, Specialty Care. Prior to Pfizer he held various positions of increasing responsibility at Merck and Co, Inc. from April 1993 to November 2003. Mr. Thompson holds a Bachelor’s degree in Commerce from McMaster University and a Master’s degree in Business Administration from the University of Notre Dame.

Always perform your own due diligence before making any decisions regarding the buy or sale of any stock. The below data on ANTH is provided without any guarantee of its accuracy.

Ticker Symbol ANTH
Last Price a/o 9:45 EST  $               2.39
Average Volume 618,000
Market Cap $56 million
Sales $2.1 million
Shares Outstanding 38 million
Share Float 36.8 million
Shortable Yes
Optionable Yes
Inside Ownership 12.46%
Short Float 15.90%
Short Interest Ratio 9.46
Quarterly Return -51%
YTD Return -68%
Year Return -68.00%